Celcuity LLC

Yahoo Finance • 2 days ago

Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump

Key Points David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% of Dalvey’s total indirect holdings prio... Full story

Yahoo Finance • 6 days ago

Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances

Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here. Apis Flagship Fund delivered strong performance in the fourth quarter of 2025, with the Fund up 10.0% net for the... Full story

Yahoo Finance • 2 months ago

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presen... Full story

Yahoo Finance • 2 months ago

Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Hea... Full story

Yahoo Finance • 3 months ago

Block upgraded, Dell downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI A... Full story

Yahoo Finance • 3 months ago

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug... Full story

Yahoo Finance • 3 months ago

Block upgraded, Dell downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Hold fr... Full story

Yahoo Finance • 3 months ago

Celcuity outlines $2.5B–$3B peak revenue potential for gedatolisib amid accelerated launch preparations

Earnings Call Insights: Celcuity (CELC) Q3 2025 MANAGEMENT VIEW * CEO Brian Sullivan highlighted significant clinical and regulatory milestones, stating, "We made significant progress achieving a number of clinical and regulatory miles... Full story

Yahoo Finance • 3 months ago

Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (“ESMO”) Congress Prese... Full story

Yahoo Finance • 3 months ago

After-Hours Earnings Report for November 12, 2025 : CSCO, MFC, FLUT, PAAS, ASND, TTEK, CLBT, CELC, GRAL, DLO, LB, WBTN

The following companies are expected to report earnings after hours on 11/12/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Cisco Systems, Inc. (CSCO)is reporting for the quarter ending October 31, 202... Full story

Yahoo Finance • 3 months ago

Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.

Celcuity hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534% this year. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for t... Full story

Yahoo Finance • 4 months ago

Stocks Rally on Easing Trade Tensions and Solid Q3 Earnings

The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.07%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +1.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.30%.  December E-mini S&P futures (ESZ25) rose +1.12%, and Decem... Full story

Yahoo Finance • 4 months ago

Noteworthy Monday Option Activity: UNH, REPL, CELC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has been traded thus far today, a contract... Full story

Yahoo Finance • 4 months ago

Stocks Supported by Trade Hopes and Earnings Optimism

The S&P 500 Index ($SPX) (SPY) today is up +1.01%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.86%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.29%.  December E-mini S&P futures (ESZ25) are up +1.01%, and December E-mini Nas... Full story

Yahoo Finance • 4 months ago

Stocks Rise as US-China Trade Tensions Ease

The S&P 500 Index ($SPX) (SPY) today is up +0.71%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.51%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.89%.  December E-mini S&P futures (ESZ25) are up +0.75%, and December E-mini Nas... Full story

Yahoo Finance • 4 months ago

Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients... Full story

Yahoo Finance • 4 months ago

Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)

Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 4 months ago

Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial

PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed... Full story

Yahoo Finance • 4 months ago

ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves

The ClearBridge Small Cap Strategy underperformed its Russell 2000 Index benchmark during the third quarter, despite registering gains in 10 of the 11 sectors in which it was invested during the quarter. ClearBridge Small Cap Strategy, in... Full story